Expression of concern: 'Two-day versus seven-day course of levofloxacin in acute COPD exacerbation: a randomized controlled trial'

No authors listed

No authors listed. Ther Adv Respir Dis. 2023 Jan-Dec.

. 2023 Jan-Dec:17:17534666231190750.

doi: 10.1177/17534666231190750.

No abstract available

Expression of concern for

Two-day versus seven-day course of levofloxacin in acute COPD exacerbation: a randomized controlled trial.
Messous S, Trabelsi I, Bel Haj Ali K, Abdelghani A, Ben Daya Y, Razgallah R, Grissa MH, Beltaief K, Mezgar Z, Belguith A, Bouida W, Boukef R, Boubaker H, Msolli MA, Sekma A, Nouira S. Messous S, et al. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221099729. doi: 10.1177/17534666221099729. Ther Adv Respir Dis. 2022. Retraction in: Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251362671. doi: 10.1177/17534666251362671. PMID: 35657073 Free PMC article. Retracted. Clinical Trial.